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STEM CELLS
In recent years stem cell therapy has
emerged as a potential treatment for
neonatal ischemic brain injury. The effi-
cacy of cell- based therapies in restoring
damaged brain tissue has been tested in
a multitude of models for different CNS
diseases. Several different stem and pro-
genitor cell populations have been utilized
as cell-based therapy, including neural
stem cells, embryonic stem cells, human
umbilical cord blood cells (HUBCs),
hematopoietic stem and progenitor cells,
andmesenchymal stem cells (MSCs). Most
stem cell types appear to enhance recov-
ery to some extent (Pimentel-Coelho and
Mendez-Otero, 2010). However, because
of their low immunogenicity, availability
and positive results obtained from pre-
clinical studies, MSCs are a particularly
promising candidate to repair the dev-
astating effects that are associated with
neonatal stroke. MSCs were first iso-
lated and identified in bone marrow, but
can now be isolated from many tissues,
including adipose tissue, muscle, skin and
extraembryonic tissues like the placenta,
umbilical cord and Wharton’s jelly. The
latter sources are of particular interest for
neonates that experience an ischemic event
around the time of birth, at which time
cells can be harvested and transplanted
from an autologous source. MSCs derived
from different sources have slightly dif-
ferent characteristics, but as of yet it is
unknown whether this influences their
therapeutic potential.
Our group and others have shown that
administration of MSCs reduces lesion
volume, provides positive effects on the
whitematter and improvesmotor function
(van Velthoven et al., 2012). Numerous
studies have been done under the premise
that transplanted stem cells contribute to
brain repair by directly replacing dam-
aged or lost tissue. While there is evi-
dence that transplanted cells undergo
differentiation toward neuronal lineages,
improved outcomes have been observed
even when survival of transplanted cells
is low and engrafted cells are absent. This
suggests that rather than replacing dam-
aged cells, transplanted cells may improve
outcome via indirect mechanisms. For
example,MSCs have been shown to secrete
many factors that can influence impor-
tant processes like apoptosis, neurogenesis,
angiogenesis and synaptogenesis.
MECHANISMS OF STEM CELL
MEDIATED BRAIN REPAIR—CELLULAR
ASPECTS
Although results from experimental ani-
mal models using cell-based therapies
to treat ischemic brain injury are very
promising, there are several issues that
need to be addressed. For example, the
therapeutic time window for stem cell
therapy is not well-defined. This has to
do with the fact that several models for
ischemic brain injury are being used and
several different stem cell types are being
tested. Beneficial effects of stem cells have
been observed when they are transplanted
anywhere from 3 h to 10 days after onset
of injury. In a study where MSCs were
administered at 17 days post-injury, no
beneficial effects were observed. These
data indicate that stem cells might serve
both a neuroprotective and a neurore-
generative role. This dual role is fur-
ther underlined by results showing that
apoptosis is reduced after transplantation
of stem cells, while on the other hand,
endogenous neurogenesis is enhanced. In
a recent study, multiple injections of MSCs
were shown to be more beneficial than
a single injection. Moreover, the timing
of injection may influence different repair
processes. A first injection with MSCs at
3 days after injury stimulated cell prolif-
eration and differentiation, while a sec-
ond injection at 10 days stimulated axonal
remodeling. Combined these results show
that it is imperative to investigate via
which mechanism MSCs and other stem
cells exert their beneficial effects, since
this will help identify more precise tar-
gets to improve both neuroprotection and
regeneration.
The distribution of cells within injured
brain after intravenous injection or other
modes of delivery, and potential adverse
effects of exogenous administration, have
not been thoroughly explored. The fact
that MSCs administered via intranasal
delivery migrate toward injured regions
provides a promising practical avenue for
such treatments.
The temporal-spatial effects of stem
cells often depend on the animal model
of brain injury and the source or manip-
ulation of these cells. Stem cells often
home to different regions of the brain,
with emphasis on injured or inflamed
areas. Once in the circulation, these cells
can also differentiate into a wide vari-
ety of cell types, including immune cells,
endothelial progenitors, and neuronal or
glial cell types (Liu et al., 2014). In other
organs, MSCs persist for as long as sev-
eral months. While growth factors play
a role in the efficacy of exogenous stem
cells and endogenous precursor cells, it
is likely that stem cells act as a trophic
factor factory enhancing neuroprotective
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and endogenous neurogenic capacity. In
this sense a therapeutic strategy in which
application of stem cells is combined with
growth factor administration to target a
specific event may be more beneficial in
combatting the events that cause progres-
sion of brain injury after stroke but, again,
the timing of administration would ulti-
mately determine the added repair efficacy
in the brain. Mobilization of circulating
endothelial progenitor cells (EPC) may be
another key mechanism via which stem
cells exert beneficial effects, as adequate
blood supply is essential for effective repair
of damaged tissue.
MECHANISMS OF STEM CELL
MEDIATED BRAIN
REPAIR—MOLECULAR ASPECTS
The evidence for the role of growth
factors on cell proliferation and tissue
repair after stem cell transplantation
includes increased expression of a num-
ber of factors that lead to proliferation
and integration of endogenous cells into
neural networks, while also enhancing
angiogenesis. As mentioned, HUBCs
have demonstrated an ability to express
neuronal, astrocytic, and oligodendro-
cyte markers in vitro, but a very small
percentage of engrafted HUCBs or MSCs
survive and express neuronal phenotypes.
Many grafted cells remain undifferen-
tiated far from the lesion, where these
undifferentiated stem/progenitor cells can
directly release growth and trophic fac-
tors, or promote the release of such factors
from host brain cells. For example, MSCs
have been shown to produce trophic fac-
tors that induce survival and regeneration
of host neurons, while also producing
extracellular matrix molecules, resulting in
functional improvement at both early and
late time points after brain injury. Some
of these factors include brain-derived
neurotrophic factor (BDNF), glial -
derived neurotrophic factor (GDNF),
nerve growth factor (NGF), hepatocyte
growth factor (HGF), vascular endothelial
growth factors (VEGF), angiopoietin-1
(Ang-1) (Liu et al., 2014).
Thus, improvements in histological
injury and neurological function in ani-
mals after stem cell transplantation are
poorly understood but appear to be
secondary to effects on the microen-
vironment in the injured brain. This
could enhance host cell connections by
improving synaptic plasticity and axonal
connections, while also increasing neu-
rogenesis and angiogenesis. For exam-
ple, VEGF and its receptor are shown
to rebound after middle cerebral artery
occlusion (MCAO) in animals treated with
MSCs. Similarly, cytokines and growth
factors such as macrophage inflammatory
protein 1 (MIP-1), matrix metallopro-
teinases (MMPs), erythropoietin recep-
tor and tumor necrosis factor receptor
are increased after MSC injection (Yang
et al., 2010). This involves rapid change,
occurring by 1 week after stroke, with
continued elevation of levels at 4 weeks.
Immune modulation may also play a sig-
nificant role in this beneficial response.
There is still much to be learned about how
stem cell therapies may regulate innate
and acquired immunity. Grafted cells often
remain in the spleen and other organs
and attenuate inflammatory mediators.
This may result in increased bioavail-
ability of soluble factors such as GDNF
and BDNF.
Effects of stem cell therapy on angio-
genesis and blood vessel remodeling may
be particularly important following stroke.
Transplantation of HUCB-derived MSCs
increased the formation of new blood ves-
sels and increased cortical blood flow in
a rat model of MCAO. In vitro studies of
MSCs have demonstrated production of
a number of angiogenic factors, includ-
ing VEGF, Ang-1, IGF-1, and G-CSF.
This leads to enhancement of endothe-
lial cell proliferation and recruitment of
endogenous progenitor cells, promoting
the growth of new vessels. Angiogenesis
is mainly regulated by the VEGF/VEGF
receptor and the angiopoietin/Tie-2
signaling pathway, and the expression
of Tie-2 was increased after HUCB
transplantation.
All of these data have led to the alter-
native strategy of combining cell-based
therapy and gene delivery. In a hind limb
ischemia model, the combination of intra-
venous infusion of EPCs over-expressing
VEGF with local SDF-1 application was
more efficient in improving local blood
supply than either alone. Transplantation
of EPCs over-expressing IGF-1 has led to
inhibition of cardiac apoptosis, enhance-
ment of cardiomyocyte proliferation,
and increased capillary numbers in the
peri-infarct area. Interestingly, VEGF
over-expression in EPCs could increase the
expression of CXCR4, leading to further
enhancement of EPC homing. However,
VEGF is also known to enhance vascu-
lar permeability in the brain early after
an ischemic insult, and genetically modi-
fied MSCs expressing VEGF may actually
increase functional deficits. On the other
hand, hypoxia preconditioning enhances
VEGFR2 expression on EPCs, and accord-
ingly, augments the neovascularization
efficacy of EPCs after administration. In
addition, pre-incubating EPCs with SDF-1
enhances their pro-angiogenic potential in
hind limb ischemia.
Studies using stem cells that over-
express other neurotrophic factors, such
as BDNF, have also shown promise for
treating ischemic brain injury (Chen et al.,
2013). BDNF is secreted by brain cells
and induces neuroprotection, while pro-
moting the synaptic and axonal plas-
ticity associated with learning, memory,
and sensorimotor recovery, and increas-
ing newly born neurons in several regions
of the brain. Administration of BDNF
modified MSCs has produced therapeu-
tic benefits in a rat model of tran-
sient MCAO. Transplantation of BDNF
gene-modified human MSCs results in
increased BDNF levels in the ischemic
lesion and stronger therapeutic effects
than MSCs alone. BDNF secreted by
MSCs may protect against hyperexcitabil-
ity and modulate neuronal excitability
via downregulation of the potassium-
chloride co-transporter KCC2. BDNF may
also modulate vascular permeability and
BBB breakdown, and early effects on the
brain may be secondary to changes in
cerebral edema. Benefit has also been
demonstrated in a spinal cord injury
model with improved functional outcome
and enhanced sprouting of raphé–spinal
axons. In addition, reduction in ischemic
lesion volume and improved functional
outcome after stroke in the rat has been
seen following treatment with human
MSCs genetically modified to express
GDNF. FGF-2-modified MSCs also sig-
nificantly reduced infarct volume 14 days
after MCAO.
Overall, stem cell therapy for brain
repair after stroke and other neurological
conditions has shown benefit and may be
closer than we think.
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